215 related articles for article (PubMed ID: 30723923)
1. Exosomal Interferon-Induced Transmembrane Protein 2 Transmitted to Dendritic Cells Inhibits Interferon Alpha Pathway Activation and Blocks Anti-Hepatitis B Virus Efficacy of Exogenous Interferon Alpha.
Shi Y; Du L; Lv D; Li H; Shang J; Lu J; Zhou L; Bai L; Tang H
Hepatology; 2019 Jun; 69(6):2396-2413. PubMed ID: 30723923
[TBL] [Abstract][Full Text] [Related]
2. Hepatic exosomes with declined MiR-27b-3p trigger RIG-I/TBK1 signal pathway in macrophages.
You J; Wu W; Lu M; Xie Y; Miao R; Gu M; Xi D; Yan W; Wu D; Wang X; Chen T; Ning Q; Han M
Liver Int; 2022 Jul; 42(7):1676-1691. PubMed ID: 35460174
[TBL] [Abstract][Full Text] [Related]
3. Liver Gene Expression Profiles Correlate with Virus Infection and Response to Interferon Therapy in Chronic Hepatitis B Patients.
Wu HL; Hsiao TH; Chen PJ; Wong SH; Kao JH; Chen DS; Lu JY; Lu TP; Chen Y; Chuang EY; Tu HC; Liu CJ
Sci Rep; 2016 Aug; 6():31349. PubMed ID: 27546197
[TBL] [Abstract][Full Text] [Related]
4. Genetic variation in STAT4 predicts response to interferon-α therapy for hepatitis B e antigen-positive chronic hepatitis B.
Jiang DK; Wu X; Qian J; Ma XP; Yang J; Li Z; Wang R; Sun L; Liu F; Zhang P; Zhu X; Wu J; Chen K; Conran C; Zheng SL; Lu D; Yu L; Liu Y; Xu J
Hepatology; 2016 Apr; 63(4):1102-11. PubMed ID: 26704347
[TBL] [Abstract][Full Text] [Related]
5. HBeAg-negative chronic hepatitis B: why do I treat my patients with pegylated interferon-alfa?
Vlachogiannakos J; Papatheodoridis GV
Liver Int; 2014 Feb; 34 Suppl 1():127-32. PubMed ID: 24373089
[TBL] [Abstract][Full Text] [Related]
6. The comparison of the efficacy of pegylated interferon α-2a and α-2b in chronic hepatitis B patients.
Dogan UB; Golge N; Akin MS
Eur J Gastroenterol Hepatol; 2013 Nov; 25(11):1312-6. PubMed ID: 23652913
[TBL] [Abstract][Full Text] [Related]
7. Reduction of HBV replication prolongs the early immunological response to IFNα therapy.
Tan AT; Hoang LT; Chin D; Rasmussen E; Lopatin U; Hart S; Bitter H; Chu T; Gruenbaum L; Ravindran P; Zhong H; Gane E; Lim SG; Chow WC; Chen PJ; Petric R; Bertoletti A; Hibberd ML
J Hepatol; 2014 Jan; 60(1):54-61. PubMed ID: 23994382
[TBL] [Abstract][Full Text] [Related]
8. Brief Report: Blockade of TANK-Binding Kinase 1/IKKɛ Inhibits Mutant Stimulator of Interferon Genes (STING)-Mediated Inflammatory Responses in Human Peripheral Blood Mononuclear Cells.
Frémond ML; Uggenti C; Van Eyck L; Melki I; Bondet V; Kitabayashi N; Hertel C; Hayday A; Neven B; Rose Y; Duffy D; Crow YJ; Rodero MP
Arthritis Rheumatol; 2017 Jul; 69(7):1495-1501. PubMed ID: 28426911
[TBL] [Abstract][Full Text] [Related]
9. Addition of nucleoside analogues to peg-IFNα-2a enhances virological response in chronic hepatitis B patients without early response to peg-IFNα-2a: a randomized controlled trial.
Xu Y; Wang X; Liu Z; Zhou C; Qi W; Jiao J; Yu F; Guo H; Zhao P; Wang J
BMC Gastroenterol; 2017 Aug; 17(1):102. PubMed ID: 28854883
[TBL] [Abstract][Full Text] [Related]
10. Predictive Value of Serum Albumin, Iron, Ferritin, and Hepcidin for Antiviral Efficacy of IFNα Treatment in Patients with Chronic Hepatitis B.
Liu Q; Liu F; Duan W; Wei Y; Zhou T; Zhang H; Duan Z; Zhou Q; Wang Q
Ann Clin Lab Sci; 2024 Mar; 54(2):217-223. PubMed ID: 38802153
[TBL] [Abstract][Full Text] [Related]
11. Comparison of 208-week sequential therapy with telbivudine and entecavir in HBeAg-positive chronic hepatitis B patients with suboptimal responses to 24 weeks of Peg-IFNα-2a therapy: An open-labelled, randomized, controlled, "real-life" trial.
Luo XD; Chen XF; Zhou Y; Chen XP
J Viral Hepat; 2017 Nov; 24 Suppl 1():36-42. PubMed ID: 29082651
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the efficacy of thymosin alpha-1 and interferon alpha in the treatment of chronic hepatitis B: a meta-analysis.
Yang YF; Zhao W; Zhong YD; Yang YJ; Shen L; Zhang N; Huang P
Antiviral Res; 2008 Feb; 77(2):136-41. PubMed ID: 18078676
[TBL] [Abstract][Full Text] [Related]
13. [Relationship between the suppressor of cytokine signaling 3 expression and antiviral efficacy of nucleos(t)ide and interferon alpha therapy for chronic hepatitis B].
Wang YL; Wu WY; You J; Yan WM; Luo XP; Ning Q; Han MF
Zhonghua Gan Zang Bing Za Zhi; 2019 Jan; 27(1):27-32. PubMed ID: 30685920
[No Abstract] [Full Text] [Related]
14. Matrix Metalloproteinase 9 Facilitates Hepatitis B Virus Replication through Binding with Type I Interferon (IFN) Receptor 1 To Repress IFN/JAK/STAT Signaling.
Chen J; Xu W; Chen Y; Xie X; Zhang Y; Ma C; Yang Q; Han Y; Zhu C; Xiong Y; Wu K; Liu F; Liu Y; Wu J
J Virol; 2017 Apr; 91(8):. PubMed ID: 28122987
[TBL] [Abstract][Full Text] [Related]
15. Engineered anti-PDL1 with IFNα targets both immunoinhibitory and activating signals in the liver to break HBV immune tolerance.
Meng CY; Sun S; Liang Y; Xu H; Zhang C; Zhang M; Wang FS; Fu YX; Peng H
Gut; 2023 Aug; 72(8):1544-1554. PubMed ID: 36316098
[TBL] [Abstract][Full Text] [Related]
16. In vitro effect of thymosin-alpha1 and interferon-alpha on Th1 and Th2 cytokine synthesis in patients with eAg-negative chronic hepatitis B.
Loggi E; Gramenzi A; Margotti M; Cursaro C; Galli S; Vitale G; Grandini E; Scuteri A; Vukotic R; Andreone P; Bernardi M
J Viral Hepat; 2008 Jun; 15(6):442-8. PubMed ID: 18221304
[TBL] [Abstract][Full Text] [Related]
17. An interferon-like small chemical compound CDM-3008 suppresses hepatitis B virus through induction of interferon-stimulated genes.
Furutani Y; Toguchi M; Shiozaki-Sato Y; Qin XY; Ebisui E; Higuchi S; Sudoh M; Suzuki H; Takahashi N; Watashi K; Wakita T; Kakeya H; Kojima S
PLoS One; 2019; 14(6):e0216139. PubMed ID: 31188831
[TBL] [Abstract][Full Text] [Related]
18.
Xie DY; Wang SM; Yang JM; Wang LH; Chen HY; Huai C; Shang J; Mao Q; Lei CL; Luo GH; Qian J; Lu DR
World J Gastroenterol; 2016 Nov; 22(44):9813-9821. PubMed ID: 27956805
[TBL] [Abstract][Full Text] [Related]
19. [Interferon in hepatitis B].
García Buey L; González Mateos F; Moreno Otero R
Enferm Infecc Microbiol Clin; 2008 May; 26 Suppl 7():19-31. PubMed ID: 19100228
[TBL] [Abstract][Full Text] [Related]
20. JAK1 gene polymorphisms are associated with the outcomes of hepatitis B virus infection, but not with α interferon therapy response in a Han Chinese population.
Chen K; Min H; Wu X; Zhu X; Li Z; Li H; Liu Y
Genet Test Mol Biomarkers; 2012 Oct; 16(10):1206-10. PubMed ID: 22901011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
